Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) from a sell rating to a hold rating in a research note published on Sunday morning,Wall Street Zen reports.

A number of other research firms have also weighed in on DMRA. HC Wainwright reiterated a “buy” rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. Jefferies Financial Group started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They set a “buy” rating and a $50.00 target price on the stock. Guggenheim upped their target price on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, September 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Damora Therapeutics, Inc. Common Stock presently has an average rating of “Buy” and an average target price of $46.50.

Damora Therapeutics, Inc. Common Stock Trading Down 8.3%

Shares of NASDAQ:DMRA opened at $18.56 on Friday. The stock has a 50 day moving average of $26.15 and a 200 day moving average of $25.87. The company has a market cap of $1.15 billion, a PE ratio of -5.51 and a beta of 1.43. Damora Therapeutics, Inc. Common Stock has a 12-month low of $4.95 and a 12-month high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its earnings results on Monday, August 10th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.06. Equities research analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett purchased 12,500 shares of the company’s stock in a transaction on Friday, September 25th. The stock was acquired at an average cost of $20.23 per share, for a total transaction of $252,875.00. Following the purchase, the chief executive officer directly owned 512,500 shares of the company’s stock, valued at $10,367,875. This trade represents a 2.50% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Several institutional investors and hedge funds have recently modified their holdings of DMRA. Squarepoint Ops LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter worth $303,000. Arizona State Retirement System purchased a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter valued at $260,000. Seven Fleet Capital Management LP purchased a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter valued at $7,398,000. Finally, Braidwell LP bought a new position in Damora Therapeutics, Inc. Common Stock during the second quarter valued at $42,146,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.